Company Overview and News
2018-09-24 seekingalpha - 1
Cobalt spot prices were slightly down in September but appear to have stabilized just below US$30/lb.
SIE PIO CLA PANRF CCZ PAN HAV MCR KBGCF CTM AXE ECSIF IGO VIC AOU HIG PCRCF PLM.RT SNNAF FQM MCRZF BXTMF MLX PSDNF POM AYR JRV SHERF CDU RGARF CHK MCRZY FTMDF KAT RER CSSQF GMRSF CZN PGM GBLEF NZRIF AZS GLCNF DLE MALRY HBNRF MEI PIONF BPLNF GAL CZI AMSLF HMI MIN POS AUZ RNX GME FQVLF AQR PTNUF WCTXD FT HNLMF ORR CDNMD 3993 UMICY CDNMF IIDDY AEOMF USCFF FTSSF KATFF BBBMF MLXEF OZMLF PLM CNJ AZRMF HLPCF BPL BHP OZL MALRF ARV
Platina Resources Ltd (ASX:PGM) has begun metallurgical testing to develop an aluminium-scandium master alloy using scandium oxide produced at its Owendale pilot plant.
Platina Resources Ltd (ASX:PGM) has produced a small sample of high purity alumina (HPA) in its metallurgical testing program for its Owendale Scandium-Cobalt-Nickel Project in New South Wales.
Platina Resources Limited (ASX:PGM) non-executive director John Anderson has demonstrated his confidence in the company’s focus on scandium by acquiring shares on-market.
PGM PTNUF SSLZY STO
Cobalt miner news - BHP seeking to add cobalt sulphate from Nickel West operation. China Molybdenum net profit set to surge between 271.21% and 295.16%.
SIE PIO CLA PANRF BLT CCZ PAN HAV MCR KBGCF CTM AXE ECSIF IGO VIC BAR AOU HIG PCRCF PLM.RT SNNAF FQM MCRZF BXTMF MLX PSDNF POM AYR CDU RGARF CHK MCRZY FTMDF KAT RER BBL CSSQF BHPLF GMRSF CZN PGM GBLEF NZRIF AZS GLCNF DLE HBNRF MEI PIONF GAL CZI AMSLF BPLNF HMI POS AUZ RNX GME FQVLF AQR PTNUF FT BHPBF HNLMF ORR CDNMD 3993 UMICY CDNMF IIDDY AEOMF USCFF FTSSF KATFF BBBMF MLXEF OZMLF PLM BHP CNJ AZRMF HLPCF BPL BHP OZL ARV
Platina Resources Ltd (ASX:PGM) and joint venture partner Artemis Resources Ltd (ASX:ARV) will target conglomerate-hosted gold potential at their Munni Munni Project joint venture.
PGM PTNUF ARV
Platina Resources Ltd (ASX:PGM) has increased the JORC resource estimate at its 100% owned Owendale Scandium-Cobalt-Nickel Project in central New South Wales.
Platina Resources Limited (ASX:PGM) is making excellent progress advancing the definitive feasibility study (DFS) on its Owendale Scandium-Cobalt-Nickel Project in central New South Wales.
PGM PTNUF ARV
Hylea Metals (ASX:HCO) has intersected high-grades of scandium during the maiden drilling program of the Tiger’s Creek battery metals prospect within its Hylea Project in New South Wales.
AUZ PGM PTNUF CLQ AMSLF
Platina Resources Limited (ASX:PGM) has produced the first refined scandium oxide from its Owendale Scandium-Cobalt-Nickel Project in central New South Wales with samples to be sent to potential customers.
Platina Resources Limited (ASX:PGM) has intersected higher than expected scandium mineralisation along with high-grade cobalt and platinum at the Owendale project in central New South Wales.
Cobalt market news - Darton forecasts 40% growth in cobalt demand in 2018. Tony Southgate (ERG) says: "The cobalt boom is guaranteed for the next seven to 10 years."
SIE PIO CLA PANRF RIO CCZ PAN HAV MCR KBGCF CTM FCX AXE IGO VIC BAR AOU HIG PCRCF PLM.RT SNNAF FQM MCRZF BXTMF MLX PSDNF POM AYR SHERF CDU RGARF CHK MCRZY CLQ FTMDF KAT RIO RER CSSQF GMRSF CZN PGM GBLEF NZRIF RIO AZS GLCNF DLE HBNRF MEI PIONF CZI AMSLF BPLNF HMI POS AUZ RNX RTPPF GME RTNTF FQVLF AQR PTNUF FT HNLMF ORR CDNMD 3993 UMICY CDNMF IIDDY AEOMF USCFF FTSSF KATFF BBBMF MLXEF OZMLF PLM CNJ AZRMF HLPCF BPL BHP OZL ARV
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to ASX:PGM / PLATINA RESOURCES LIMITED on message board site Silicon Investor.